Effect of Drug Utilization Controls and Coverage on Quality, Cost and Outcomes among Patients with Mental Illness
December 4, 2008 This presentation, given at the Pharmacotherapy Summit, explored the adverse effects of a Medicaid drug benefit cap used in 12-15 states. The largest impact of the cap has been among patients with mental illness; in addition to decreasing essential doses of drugs used to treat psychosis and bipolar disorder, the cap may increase total health care costs . . .
